Insulet Corp
Related Articles
Why Insulet Stock Is Soaring after Q2 Results
Insulet (PODD) stock has risen 19.27% today to $140.65, soaring in response to the company’s strong second-quarter results yesterday.
What Are Insulet’s Key Growth Drivers in 2019?
In the first quarter, Insulet (PODD) secured coverage for its Omnipod devices for 5 million Medicare and Medicaid members.
Analyzing Tandem Diabetes and Insulet’s International Strategy
Tandem Diabetes Care (TNDM) reaffirmed its fiscal 2019 international market revenue guidance of $45 million to $50 million.
Tandem or Insulet: Who Is Reporting Faster Pump Uptake?
In the first quarter, Tandem Diabetes Care (TNDM) shipped 14,700 insulin pumps, a YoY rise of 232%.
Tandem Diabetes and Insulet: Comparing Revenue Growth
In its first-quarter earnings conference call, Tandem Diabetes Care (TNDM) increased its fiscal 2019 revenue guidance.
How Analysts Rate Tandem Diabetes Care and Insulet
Until the start of 2017, the insulin pump technology space was mainly dominated by big companies such as Medtronic and Johnson & Johnson.
Why Tandem Diabetes Care Stock Soared Over 1,480% in 2018
Tandem Diabetes Care (TNDM) stock grew from $2.36 on December 29, 2017, to reach $37.31 at the close of market on December 28, 2018, an increase of ~1,481% this year.
Tandem Diabetes Care Stock Has Skyrocketed in 2018
On November 21, Tandem Diabetes Care stock closed at $32.63, a ~14.69% rise from its previous day’s close of $28.45.
Why Wall Street Is Still Bullish on Tandem Stock
This month, of the total ten analysts covering Tandem Diabetes Care (TNDM), seven have given the stock a “buy” or higher rating and three have given it a “hold” rating.
Tandem Diabetes Care’s Operational Performance
Tandem Diabetes Care’s (TNDM) cost of sales increased from $15.13 million in the third quarter of 2017 to $24.47 million in the third quarter of 2018.
Why Tandem Should Be on Your Stock Radar
Tandem Diabetes Care’s (TNDM) key focus is its t:slim X2 insulin delivery system, which is designed to display continuous glucose monitoring directly on a pump’s home screen.
A Look into Johnson & Johnson’s Diabetes Care Business
In the US and international markets, Johnson & Johnson’s Diabetes Care segment generated third-quarter net revenues of $125.0 million and $190.0 million, respectively.
Most Analysts Are Bullish on Tandem Stock
Seven of the total ten analysts covering Tandem Diabetes Care (TNDM) in October 2018 have given Tandem a “buy” or higher rating.
What Can We Expect from Tandem’s Bottom Line in Third Quarter?
Tandem Diabetes Care (TNDM) is expected to incur a net loss of $18.22 million in the third quarter of 2018.
How Will Tandem’s Q3 Operational Performance Stack Up?
The cost of goods sold incurred by Tandem Diabetes Care (TNDM) is expected to increase in line with revenues by 55.66% from $14.4 million in the third quarter of fiscal 2017 to $22.41 million in the third quarter of fiscal 2018.
Could JNJ’s Medical Device Business Report Strong Growth in Q3?
Twelve of JNJ’s medical device business platforms are worth more than $1.0 billion.
Why TNDM’s Stock Price Rose 7.4% on September 25
On September 25, Tandem Diabetes Care’s stock price closed at $47.84, which represents ~7.43% growth from the close of $44.53 on September 24.
Johnson & Johnson’s Medical Device Business: Q2 2018 Estimates
Johnson & Johnson’s medical device business has been going through a major restructuring after its performance weakened in recent years due to competition.
What Tandem Diabetes Care Expects for This Year
In fiscal 2018, Tandem Diabetes Care (TNDM) expects sales at the mid-to-upper end of its $132 million–$140 million guidance.
Tandem Diabetes Care’s International Expansion Strategy
Tandem Diabetes Care (TNDM) is slated to begin its international expansion later this year to capture opportunities arising after Johnson & Johnson’s (JNJ) exit from the insulin pump market, which was announced in October 2017.
Tandem Diabetes Care’s Stock Performance This Month
On June 26, Tandem Diabetes Care (TNDM) ended the trading day at $23.64, ~7.3% lower than its 52-week low of $25.50 reached on June 22, triggered by news of the FDA’s approval of the company’s new insulin pump.
MDT’s Diabetes Business Could Significantly Boost Its Revenue
In fiscal Q4 2018, Medtronic’s (MDT) Diabetes segment generated revenue of $645 million compared to $512 million in fiscal 2017.
Tandem Diabetes Care Rallies on FDA Approval of Insulin Pump
Today, Tandem Diabetes Care (TNDM) opened~16.2% higher than yesterday’s closing price of $20.31, triggered by the news of FDA approval of its t:slim X2 insulin pump with Basal IQ technology.
Analysts’ Views on Tandem Diabetes Care after Its FDA Approval
After the market closed on June 21, Tandem Diabetes Care (TNDM) announced the FDA’s approval of its t:slim X2 insulin pump.
Johnson & Johnson Accepts Sale of Its LifeScan Business
On June 12, Johnson & Johnson (JNJ) announced it had accepted a $2.1 billion offer for the sale of its LifeScan business, which manufactures blood glucose monitoring devices and OneTouch products, from private equity company Platinum Equity.
Why Abiomed’s Product Pipeline Looks Promising
Abiomed (ABMD) is strategically focused on the market penetration of the company’s family of Impella heart pumps.
What Analysts Recommend for Abiomed and Peers in February 2018
Of the ten analysts covering Abiomed (ABMD) in February 2018, five analysts have given the stock a “strong buy” rating.
Analysts’ Ratings for NxStage Medical and Peers in February 2018
NxStage Medical sells its products and offers services in three markets: home, critical care, and in-center.
BDX’s Planned Product Launches in 2018
Under the BD Medical segment, BDX has started shipping IV (intravenous) solutions in partnership with Fresenius.
J&J’s Medical Device Segment Registered Strong Growth in 4Q17
Johnson & Johnson (JNJ) released its 4Q17 and fiscal 2017 results on January 23, 2018.
JNJ Exits Insulin Pump Business amid Stiff Competition
On October 5, 2017, & Johnson’s (JNJ) diabetes care company, Animas, announced its plans to exit the insulin pump business.
Medtronic Is Focused on Developing Glucose Monitoring Solutions
According to Medtronic (MDT), there are about 450 million diabetes patients in the world.
Medtronic Saw Several Challenges during Launch of MiniMed 670G
In fiscal 2H17, Medtronic launched the priority access program to first target those patients who were interested in purchasing MiniMed 670G.
What’s Medtronic’s Long-Term Growth Strategy for Its Diabetes Business?
Medtronic (MDT) expects its diabetes business to witness a temporary sequential drop in revenues in 2Q18 and then return back to growth in the second half of fiscal 2018.
What’s Medtronic’s Strategy to Drive Growth in Diabetes Group?
In the US, Medtronic has entered outcomes-based contracts with UnitedHealth Group and Aetna.
Medtronic Aims to Become a Holistic Diabetes Management Company
Medtronic (MDT) is currently a leading supplier of insulin pumps and sensors to type one diabetes patients in the US.
Medtronic’s Diabetes Franchise to See Double-Digit Growth in 2019
In 1Q18, Medtronic (MDT) had to prioritize supplying sensors to its existing customers.
What Affected the Performance of Medtronic’s Diabetes Franchise?
Medtronic (MDT) has been witnessing higher-than-anticipated demand for its automated insulin dosing technology around the world.
Zeltiq Aesthetics Extends 3-Day Rally to 4
Zeltiq Aesthetics closed at $29.73 and was trading above the 20-day moving average price of $26.80 on June 2. That extended its three-day rally to four.
Dexcom Tanks on Profit Booking after Directors Increase Stakes
Dexcom (DXCM) was the worst-performing stock within the iShares U.S. Medical Devices ETF (IHI) on May 26, 2016.
Profit Booking Leaves the iShares US Medical Devices ETF (IHI) in the Red
On May 19, markets declined, with the SPDR S&P 500 ETF dropping by 0.3% and the iShares US Medical Devices ETF (IHI) declining by 0.8%.